RecruitingNot Applicable

ImproviNg rEnal Outcomes Following Coronary angiograPhy and/or percuTaneoUs coroNary intErventions

Canada1,158 participantsStarted 2021-06-28

Plain-language summary

The NEPTUNE triple-blind, active-placebo, adaptive, pragmatic, randomized trial aims to evaluate the effectiveness of a new intra-venous hydration strategy guided by left ventricular end-diastolic pressure (LVEDP), amount of contrast used, and baseline renal function, to prevent contrast-induced acute kidney injury (CI-AKI) and patient-oriented clinical endpoints in all-comer patients undergoing coronary angiogram and/or percutaneous coronary intervention (PCI).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 years; * Planned coronary angiogram and/or PCI; * Willingness to participate and to attend study visits; * Expected life expectancy ≥6 months. Exclusion Criteria: * Cardiogenic or non-cardiogenic shock at the time of the procedure; * Emergent procedures (e.g. STEMI); * Iodine-based contrast media received within 2 days; * Presence of Intra-Aortic Balloon Pump (IABP); * Cardiac arrest within 24 hours; * Pre-procedural AKI defined using the modified KDIGO criteria within 7 days; * Renal replacement therapy; * Severe aortic or mitral disease; * LVEF \<30%.

What they're measuring

Contrast-induced acute kidney injury

Timeframe: 7 days

Trial details

NCT IDNCT04936607

SponsorMontreal Heart Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-01-30

Contact for this trial

Guillaume Marquis-Gravel, MD, MSc

(514) 376-3330 guillaume.marquis.gravel@umontreal.ca

View on ClinicalTrials.gov More Contrast-Induced Acute Kidney Injury trials